.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
Baxter
AstraZeneca
UBS
Boehringer Ingelheim
Teva
Accenture
Daiichi Sankyo
Argus Health

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Stably tethered structures of defined compositions with multiple functions or binding specificities
Abstract: The present invention concerns stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:14/521,013
Patent Claims:1. A stably tethered structure comprising: a) two copies of a first fusion protein comprising a dimerization and docking domain (DDD) selected from the group consisting of residues 1-44 of human protein kinase A RII.alpha. and RII.beta. fused to a first protein or peptide, wherein the first protein or peptide is a first monoclonal IgG antibody or antigen-binding fragment thereof; and b) one copy of a second fusion protein comprising the amino acid sequence selected from the group consisting of the anchoring domain (AD) of A-kinase anchoring protein (AKAP) fused to a second protein or peptide, wherein the second protein or peptide is a second monoclonal IgG antibody or antigen-binding fragment thereof; wherein the first and second antibody or antigen-binding fragment thereof bind to a human antigen selected from the group consisting of CD20, CD22, CD74, CEACAM5 (carcinoembryonic antigen), EGP-1 (epithelial glycoprotein-1), HLA-DR, IGF-1R (insulin-like growth factor type I receptor), and AFP (.alpha.-fetoprotein), wherein the two copies of the DDD bind to the AD to form a stably tethered structure and wherein the antigen-binding fragment is selected from the group consisting of a Fab antibody fragment, a Fab' antibody fragment, an scFv antibody fragment, a diabody and a single domain antibody (DAB).

2. The stably tethered structure of claim 1, further comprising at least one diagnostic agent or therapeutic agent attached to the first or second fusion proteins.

3. The stably tethered structure of claim 1, wherein the first and second proteins or peptides are selected from the group consisting of an IgG antibody, a Fab antibody fragment and an scFv antibody fragment.

4. The stably tethered structure of claim 2, wherein the therapeutic agent is selected from the group consisting of abrin, amantadine, amoxicillin, amphotericin B, ampicillin, azaribine, anastrozole, azacytidine, aztreonam, azithromycin, bacitracin, trimethoprim, sulfamethoxazole, bifonazole, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carbenicillin, caspofungin, carmustine, cefaclor, cefazolin, cephalosporins, cefepime, ceftriaxone, cefotaxime, celecoxib, chlorambucil, chloramphenicol, cisplatinum, irinotecan (CPT-11), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, diphtheria toxin, DNase I, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), doxycycline, cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, estrogen receptor binding agents, etoposide, etoposide glucuronide, etoposide phosphate, erythrocycline, erythromycin, farnesyl-protein transferase inhibitors, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, ganciclovir, gentamycin, gelonin, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, isoniazid, itraconazole, kanamycin, ketoconazole, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, minocycline, naftifine, nalidixic acid, neomycin, navelbine, nitrosourea, nystatin, ranpirnase, oxacillin, paromomycin, penicillin, pentamidine, piperacillin-tazobactam, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, pokeweed antiviral protein, Pseudomonas exotoxin, Pseudomonas endotoxin, raloxifene, rapLR1, ribonuclease, ricin, semustine, rifabutin, rifampin, rimantadine, streptomycin, sulfamethoxazole, sulfasalazine, Staphylococcal enterotoxin-A, streptozocin, tamoxifen, taxanes, testosterone propionate, tetracycline, thalidomide, thioguanine, thiotepa, teniposide, topotecan, transplatinum, uracil mustard, valacyclovir, vancomycin, vinblastine, vinorelbine, vincristine, zanamir, zithromycin, or a combination thereof.

5. The stably tethered structure of claim 2, wherein the therapeutic agent is a radioisotope selected from the group consisting of .sup.225Ac, .sup.211At, .sup.212Bi, .sup.213Bi, .sup.14C, .sup.51Cr, .sup.36Cl, .sup.45Ti, .sup.57Co, .sup.58Co, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.166Dy, .sup.152Eu, .sup.18F, .sup.67Ga, .sup.68Ga, .sup.195mHg, .sup.166Ho, .sup.3H, .sup.111In, .sup.123I, .sup.124I, .sup.125I, .sup.131I, .sup.52Fe, .sup.59Fe, .sup.177Lu, .sup.191Os, .sup.212Pb, .sup.32P, .sup.33P, .sup.142Pr, .sup.195mPt, .sup.223Ra, .sup.186Re, .sup.188Re, .sup.189Re, .sup.47Sc, .sub.75Se, .sup.111Ag, .sup.153Sm, .sup.89Sr, .sup.35S, .sup.161Tb, .sup.94mTc, .sup.99mTc, .sup.86Y, .sup.90Y, and .sup.89Zr.

6. The stably tethered structure of claim 2, wherein the therapeutic agent is an anti-angiogenic agent selected from the group consisting of angiostatin, baculostatin, canstatin, maspin, anti-VEGF antibodies, anti-placental growth factor antibodies, anti-Flk-1 antibodies, anti-Flt-1 antibodies, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, Gro-.beta., thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, pentosan polysulphate, angiopoietin 2, interferon-alpha, herbimycin A, 16K prolactin fragment, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, angiostatin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 and minocycline.

7. The stably tethered structure of claim 2, wherein the therapeutic agent is selected from the group consisting of a bacterial toxin, a plant toxin, ricin, abrin, a ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, Pseudomonas endotoxin, anti-P1GF, hMN-14, hA20, hLL2, L243, hCC49, hLL1, hPAM4, hRS7, hR1, Ranpirnase (Rap), Rap (N69Q), PE38, dgA, PLC, tPA, a cytokine, a growth factor, IL-4, sIL-4R, sIL-13R, anti-CD14, anti-CD111, hMN-15, TPO, EPO, a clot-dissolving agent, an enzyme and sTNF.alpha.-R.

8. A stably tethered structure comprising: a) two copies of a first fusion protein comprising a dimerization and docking domain (DDD) selected from the group consisting of residues 1-44 of human protein kinase A RII.alpha. and RII.alpha. fused to a first protein or peptide, wherein the first protein or peptide is a first IgG antibody or antigen-binding fragment thereof; and b) one copy of a second fusion protein comprising the amino acid sequence selected from the group consisting of the anchoring domain (AD) of A-kinase anchoring protein (AKAP) fused to a second protein or peptide, wherein the second protein or peptide is a second IgG antibody or antigen-binding fragment thereof; wherein the two copies of the DDD bind to the AD to form a stably tethered structure, wherein the first and second antibody are selected from the group consisting of hMN-14 (anti-CEACAM5), hA20 (anti-CD20), hLL1 (anti-CD74), hLL2 (anti-CD22), h679 (anti-HSG), L243 (anti-HLA-DR), hR1 (anti-IGF-1R), hPAM4 (anti-mucin), hMN-15 (anti-CEACAM6), and hRS7 (anti-EGP-1).

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Merck
ELSPAR
asparaginase
VIAL1010630011978-01-10► Subscribe IBC Pharmaceuticals, Inc. (Morris Plains, NJ) Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Austria297759Jul 15, 2005
Austria417067Dec 15, 2008
Austria439860Sep 15, 2009
Austria477276Aug 15, 2010
Austria500845Mar 15, 2011
Australia2002342290May 19, 2003
Australia2002342293May 19, 2003
Australia2002353943May 19, 2003
Australia2002359338May 19, 2003
Australia2003209447Oct 23, 2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Novartis
Queensland Health
US Department of Justice
Dow
Deloitte
Covington
QuintilesIMS
Teva
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot